MyMedR

Displaying all 5 publications

Abstract:

Sort:

Fulltext A case series of dextromethorphan abuse

Seed Hon Fei, Thong Kai Shin

Malaysian Journal of Psychiatry, 2018;27(2):0-0.
MyJurnal

Dextromethorphan, an over the counter cough suppressant is gaining
popularity among teenagers and young adults because of its easy availability,
relatively low price and most importantly the feeling good effects that it
brought when used in megadoses. We are reporting three cases of
dextromethorphan abuse and its clinical presentations. We discussed about
the factors that contribute to the current situation of uncontrolled usage of
dextromethorphan in our population especially in Sarawak. We also looked
into some of the steps that we can take in order to prevent the situation from
becoming worse.
Fulltext You need the operation, sign the consent: a case report on mental capacity assessment

Thong Kai Shin, Seed, Hon Fei

Malaysian Journal of Psychiatry, 2018;27(1):0-0.
MyJurnal

Decision making capacity is the basis for medical decision making. A person’s right to determine his or her own health care related decision has long been established and this forms the essence of medical treatment. This fundamental right extends to patients with mental health disorder who have the capacity to make such decisions. Where a mental disorder is evident, our experiences in the local settings suggested that clinicians are inclined to state that incapacity to decide for medical treatment is present without much assessment or exploration and explanation on the proposed treatment. Many patients with mental disorder in fact are capable at making decisions related to health care. Their rights to decide on medical treatment should be respected and not to be ignored.
Psychometric properties of Malay neuropsychiatry unit cognitive assessment tool among Alzheimer's disease patients in comparison to Malay Montreal Cognitive Assessment

Thong KS, Chee KY, Ng CG, Walterfang M, Velakoulis D

Asia Pac Psychiatry, 2016 Sep;8(3):238-40.
PMID: 26615809 DOI: 10.1111/appy.12227

This study aims to establish psychometric properties of the Malay Neuropsychiatry Unit Cognitive Assessment Tool (Malay NuCOG) in Alzheimer's disease. NuCOG was translated to Malay language and compared with Montreal Cognitive Assessment Tool on 80 individuals. The Malay NuCOG showed good internal consistency and reliability (Cronbach's alpha = 0.895). It demonstrated 100% sensitivity and 87.5% specificity at the cutoff score of 78.50/100. The Malay NuCOG is a valid and reliable cognitive instrument that is sensitive and specific for the detection of dementia and has clinical advantages in its ability to examine individual cognitive domains.
Validation of an informant-based cognitive screening tool for Parkinson disease

Chee KY, Ong KY, Mak CY, Yacob S, Yeo SC, Thrichelam N, et al.

Asia Pac Psychiatry, 2017 Dec;9(4).
PMID: 28326670 DOI: 10.1111/appy.12278

INTRODUCTION: The objective of this study was to establish the psychometric properties of the AD8 Dementia Screening Interview in patients with Parkinson disease (PD) with or without cognitive impairment using the Montreal Cognitive Assessment Tool (MoCA) for comparison.
METHODS: The AD8 was translated into Malay for Malay-speaking participants. A correlation analysis and a receiver operator characteristic curve were generated to establish the psychometric properties of the AD8 in relation to the MoCA.
RESULTS: One hundred fifty patients and their caretakers completed the AD8 and MoCA. Using a cutoff score of 1/8, the AD8 had 81% sensitivity and 59% specificity for the detection of cognitive impairment in PD. With a cutoff score of 2/8, the AD8 had 83% specificity and 64% sensitivity. The area under the receiver operator characteristic curve was 80%, indicating good-to-excellent discriminative ability.
DISCUSSION: These findings suggest that the AD8 can reliably differentiate between cognitively impaired and cognitively normal patients with PD and is a useful caregiver screening tool for PD.
Fulltext A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)

Ng CG, Abousheishaa AA, Low SY, Zainal NZ, Thong KS, Awaluddin AB, et al.

Asian Pac J Cancer Prev, 2023 Aug 01;24(8):2583-2591.
PMID: 37642043 DOI: 10.31557/APJCP.2023.24.8.2583

OBJECTIVE: Vortioxetine is a monoaminergic drug with a novel multimodal mechanism of action. We investigated its efficacy on depressive symptoms, cognitive function, and quality of life among cancer patients.
METHODS: In this multicenter, open-label, single-arm, observational study, patients received flexible doses of Vortioxetine for a period of six months. All participants were assessed at baseline and scheduled for monitoring at weeks 2, 4, 8, 12, 16, 20, and 24. Depression severity was assessed using Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI) scale. The Perceived Deficiency Questionnaire (PDQ-5) assessed the perceived cognitive difficulties in concentration, executive functioning, and memory. The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC) was used to assess the patients' quality of life. Side effects of vortioxetine were monitored using the Antidepressant Side-Effect Checklist (ASEC).
RESULTS: Patients experienced a reduction in MADRS scores from 29.89 ± 5.997 at baseline to 11.59 ± 4.629 by Week 24. The PDQ-5 scores showed significant change from Week-4, whereas the EORTC role, emotional, and cognitive functioning scores showed a significant change from Week 2 onwards. CGI-Severity scores decreased from a baseline of 4.39 ± 0.746 to 2.41 ± 1.085 by Week 24. During the 24-Weeks of therapy, around three-quarters of the patients (73.3%) had one or more adverse events reported on the ASEC. The most frequently reported TEAEs were dry mouth, insomnia, somnolence, and headache, with more than a 30% incidence rate.
CONCLUSION: Vortioxetine seems promising in the management of depression and enhancement of cognitive function and quality of life of cancer patients with Major Depressive Disorder.
.